Sanuwave Health (SNWV) Projected to Announce Quarterly Earnings on Friday

Sanuwave Health (NASDAQ:SNWV) is expected to issue its Q2 2026 results before the market opens on Friday, August 14th. Analysts expect Sanuwave Health to post earnings of ($0.03) per share and revenue of $11.50 million for the quarter. Investors can check the company’s upcoming Q2 2026 earning results page for the latest details on the call scheduled for Friday, August 7, 2026 at 8:30 AM ET.

Sanuwave Health (NASDAQ:SNWV) last released its quarterly earnings results on Thursday, August 6th. The company reported ($0.08) EPS for the quarter, missing the consensus estimate of ($0.03) by ($0.05). Sanuwave Health had a net margin of 32.38% and a return on equity of 8,163.31%. The firm had revenue of $9.74 million for the quarter, compared to analysts’ expectations of $11.50 million.

Sanuwave Health Trading Down 2.4%

SNWV opened at $5.37 on Thursday. The stock has a market capitalization of $46.18 million, a PE ratio of 22.38 and a beta of 1.48. Sanuwave Health has a one year low of $5.27 and a one year high of $45.33. The company has a debt-to-equity ratio of 8.15, a quick ratio of 0.99 and a current ratio of 1.31. The business’s 50 day moving average price is $9.09 and its 200 day moving average price is $16.46.

Analyst Ratings Changes

Separately, Weiss Ratings raised Sanuwave Health from a “hold (c-)” rating to a “hold (c)” rating in a research note on Tuesday. One research analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $51.00.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in SNWV. Praetorian PR LLC raised its holdings in shares of Sanuwave Health by 1,436.2% in the 4th quarter. Praetorian PR LLC now owns 265,000 shares of the company’s stock valued at $7,908,000 after buying an additional 247,750 shares during the period. Stifel Financial Corp purchased a new position in Sanuwave Health during the 4th quarter valued at about $5,291,000. Geode Capital Management LLC acquired a new position in Sanuwave Health in the 2nd quarter valued at about $5,184,000. Lazard Asset Management LLC acquired a new position in Sanuwave Health in the 2nd quarter valued at about $738,000. Finally, Jane Street Group LLC purchased a new stake in Sanuwave Health during the fourth quarter worth about $587,000. 42.53% of the stock is currently owned by institutional investors and hedge funds.

Sanuwave Health Company Profile

Sanuwave Health, Inc is a medical technology company specializing in the development and commercialization of non-invasive acoustic wave therapies designed to stimulate tissue regeneration and accelerate healing. The company’s proprietary Extracorporeal Pulse Activated Technology (EPAT) delivers focused acoustic pressure waves to injured or chronic wound sites, activating the body’s natural repair mechanisms. Sanuwave’s primary therapeutic areas include advanced wound care for diabetic and venous ulcers, as well as orthopedic and musculoskeletal conditions.

The company’s lead product, the dermaPACE® system, holds clearance from the U.S.